Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoid Tumor
Conditions
Carcinoid Tumor
Trial Timeline
May 1, 2006 → Dec 1, 2009
NCT ID
NCT00328497About Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) is a phase 2 stage product being developed by CASI Pharmaceuticals for Carcinoid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT00328497. Target conditions include Carcinoid Tumor.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00328497 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoid Tumor